GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.024x

Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has a cash flow conversion efficiency ratio of 0.024x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs362.20 Million ≈ $3.92 Million USD) by net assets (Rs15.40 Billion ≈ $166.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GlaxoSmithKline Pharmaceuticals Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

GlaxoSmithKline Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

GlaxoSmithKline Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GlaxoSmithKline Pharmaceuticals Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Ajanta Pharma Limited
NSE:AJANTPHARM
0.066x
GF Securities Co. Ltd
F:9GF
0.106x
Universal Display
NASDAQ:OLED
0.064x
Lazard Ltd
NYSE:LAZ
0.291x
MakeMyTrip Limited
F:MY1
-6.200x
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
0.019x
Industrias CH S. A. B. de C. V
MX:ICHB
0.004x
North Industries Group Red Arrow Co Ltd
SHE:000519
0.039x

Annual Cash Flow Conversion Efficiency for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)

The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market value of GlaxoSmithKline Pharmaceuticals Limited.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs19.51 Billion
≈ $211.03 Million
Rs12.90 Billion
≈ $139.50 Million
0.661x +101.90%
2024-03-31 Rs17.78 Billion
≈ $192.24 Million
Rs5.82 Billion
≈ $62.94 Million
0.327x +17.74%
2023-03-31 Rs17.41 Billion
≈ $188.31 Million
Rs4.84 Billion
≈ $52.37 Million
0.278x -8.66%
2022-03-31 Rs26.63 Billion
≈ $287.99 Million
Rs8.11 Billion
≈ $87.68 Million
0.304x -21.03%
2021-03-31 Rs14.99 Billion
≈ $162.12 Million
Rs5.78 Billion
≈ $62.50 Million
0.386x +43.09%
2020-03-31 Rs18.21 Billion
≈ $196.89 Million
Rs4.90 Billion
≈ $53.05 Million
0.269x +44.35%
2019-03-31 Rs21.40 Billion
≈ $231.41 Million
Rs3.99 Billion
≈ $43.19 Million
0.187x -18.79%
2018-03-31 Rs20.57 Billion
≈ $222.49 Million
Rs4.73 Billion
≈ $51.13 Million
0.230x +95.43%
2017-03-31 Rs20.07 Billion
≈ $217.03 Million
Rs2.36 Billion
≈ $25.52 Million
0.118x +43.29%
2016-03-31 Rs16.96 Billion
≈ $183.42 Million
Rs1.39 Billion
≈ $15.05 Million
0.082x -25.74%
2015-03-31 Rs24.44 Billion
≈ $264.32 Million
Rs2.70 Billion
≈ $29.21 Million
0.111x -21.83%
2014-03-31 Rs19.90 Billion
≈ $215.18 Million
Rs2.81 Billion
≈ $30.42 Million
0.141x -9.52%
2013-03-31 Rs20.07 Billion
≈ $217.03 Million
Rs3.14 Billion
≈ $33.91 Million
0.156x -9.88%
2012-03-31 Rs19.36 Billion
≈ $209.34 Million
Rs3.36 Billion
≈ $36.30 Million
0.173x -29.41%
2011-03-31 Rs19.52 Billion
≈ $211.06 Million
Rs4.79 Billion
≈ $51.84 Million
0.246x -14.23%
2010-03-31 Rs17.86 Billion
≈ $193.16 Million
Rs5.12 Billion
≈ $55.32 Million
0.286x +36.72%
2009-03-31 Rs15.76 Billion
≈ $170.39 Million
Rs3.30 Billion
≈ $35.69 Million
0.209x -9.28%
2008-03-31 Rs13.81 Billion
≈ $149.33 Million
Rs3.19 Billion
≈ $34.48 Million
0.231x +7.57%
2007-03-31 Rs12.05 Billion
≈ $130.29 Million
Rs2.59 Billion
≈ $27.97 Million
0.215x -41.44%
2006-03-31 Rs9.53 Billion
≈ $103.08 Million
Rs3.49 Billion
≈ $37.78 Million
0.367x +47.85%
2005-03-31 Rs9.24 Billion
≈ $99.90 Million
Rs2.29 Billion
≈ $24.77 Million
0.248x --

About GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO India Drug Manufacturers - General
Market Cap
$4.15 Billion
Rs383.91 Billion INR
Market Cap Rank
#4099 Global
#172 in India
Share Price
Rs2266.20
Change (1 day)
+3.02%
52-Week Range
Rs2103.20 - Rs3439.60
All Time High
Rs3466.20
About

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more